ACTRN12616000163404
Completed
未知
A pilot 'proof of concept' study to evaluate the effect of an innovative web-based resource, NSW Synergy Online Ecosystem, on general health and wellbeing in young Australians aged 16 to 25 years in three locations (Western Sydney, Central Coast and Far West).
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of Sydney
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Each participant must meet all of the following criteria to be enroled in the study:
- •\* Aged 16 to 25 years old;
- •\* Currently live in the NSW target communities of the Central Coast, Western Sydney or Far West;
- •\* Regular access to a smartphone (iPhone or Android) and the Internet; and,
- •\* Willingness to give online informed consent and willingness to comply with study protocol.
Exclusion Criteria
- •Due to the naturalistic research design, this study does not have defined exclusion criteria.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The effect of lanreotide on therapy resistant gastro-esophageal refluxpatients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry.MedDRA version: 14.1Level: LLTClassification code 10017924Term: Gastroesophageal refluxSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2013-004232-29-BEZ Brussel15
Recruiting
Not Applicable
Open pilot trial of a prototype emotional wellbeing app for adolescentsAnxietyDepressionACTRN12618000273280niversity of Auckland40
Active, not recruiting
Phase 1
A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa. - EVADEPrevention of nosocomial pneumonia caused by Pseudomonas aeruginosaMedDRA version: 20.0Level: LLTClassification code 10051190Term: Pneumonia Pseudomonas aeruginosaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2015-001706-34-HUMedImmune, LLC188
Active, not recruiting
Phase 1
Clinical trial looking at the safety and efficacy of MEDI3902 in the prevention of Pseudomonas aeruginosa pneumonia occurring in the hospitalPrevention of nosocomial pneumonia caused by Pseudomonas aeruginosaMedDRA version: 18.1Level: LLTClassification code 10051190Term: Pneumonia Pseudomonas aeruginosaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2015-001706-34-DEMedImmune, LLC429
Active, not recruiting
Phase 1
Clinical trial looking at the safety and efficacy of MEDI3902 in the prevention of Pseudomonas aeruginosa pneumonia occurring in the hospitalPrevention of nosocomial pneumonia caused by Pseudomonas aeruginosaMedDRA version: 20.0 Level: LLT Classification code 10051190 Term: Pneumonia Pseudomonas aeruginosa System Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2015-001706-34-CZMedImmune, LLC429